Security Investigation

ADMA Biologics, Inc. (NasdaqGM: ADMA)

59 Days left to seek lead plaintiff status.

Company Name:ADMA Biologics, Inc.
Stock Symbol:ADMA
Court:District of New Jersey
Class Period Start:08/09/2024
Class Period End (inclusive):03/25/2026
Filing Deadline:08/10/2026

Contact a Lawyer Now

(877) 515-1850

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. (“ADMA” or the “Company”) (NasdaqGM: ADMA) of a class action securities lawsuit.

According to the Complaint, ADMA Biologics and certain of its executives are charged with failing to disclose material information in the Offering Documents, violating federal securities laws.

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company engaged in an undisclosed related party transaction; (ii) the Company used channel stuffing to create an appearance of revenue; (iii) the Company lacked adequate internal controls; (iv) as a result, Defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you purchased securities of ADMA Biologics and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or fill out the form on this page.

The case is Mazzarino v. ADMA Biologics, Inc., et al, No. 26-cv-04793.

Click here to read the first filed complaint.